Pomerantz LLP is investigating Phreesia, Inc. for potential securities fraud following the company's announcement on March 30, 2026, that it reduced its revenue guidance for fiscal year 2027 due to weak pharmaceutical marketing and poor performance in its Networking Solutions segment. This announcement caused Phreesia's stock to fall sharply by 26.56%, closing at $8.38 per share on March 31, 2026. The investigation aims to determine if Phreesia and its executives engaged in unlawful business practices. Investors affected by the stock drop are encouraged to contact Pomerantz LLP for possible class action participation.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
ASML Holdings has raised its 2026 revenue guidance midpoint from €38 billion to €44 billion and increased its gross margin midpoint from 52% to 55%, reflecting strong growth prospects. The analyst maintains a Buy rating and raises the price target fr...
Labcorp is considered a buy due to its effective rollup strategy in a fragmented lab testing industry, driving steady and predictable growth. Automation is reducing operational costs, helping to counteract healthcare pricing pressures. The company no...
